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Background: An arteriovenous loop (AVL) enclosed in a polycarbonate chamber in vivo, produces a fibrin exudate which
acts as a provisional matrix for the development of a tissue engineered microcirculatory network.
Objectives: By administering enoxaparin sodium - an inhibitor of fibrin polymerization, the significance of fibrin scaffold
formation on AVL construct size (including the AVL, fibrin scaffold, and new tissue growth into the fibrin), growth, and
vascularization were assessed and compared to controls.
Methods: In Sprague Dawley rats, an AVL was created on femoral vessels and inserted into a polycarbonate chamber in the
groin in 3 control groups (Series I) and 3 experimental groups (Series II). Two hours before surgery and 6 hours
post-surgery, saline (Series I) or enoxaparin sodium (0.6 mg/kg, Series II) was administered intra-peritoneally.
Thereafter, the rats were injected daily with saline (Series I) or enoxaparin sodium (1.5 mg/kg, Series II) until construct
retrieval at 3, 10, or 21 days. The retrieved constructs underwent weight and volume measurements, and morphologic/
morphometric analysis of new tissue components.
Results: Enoxaparin sodium treatment resulted in the development of smaller AVL constructs at 3, 10, and 21 days.
Construct weight and volume were significantly reduced at 10 days (control weight 0.337  0.016 g [Mean  SEM] vs
treated 0.228  0.048, [P < .001]: control volume 0.317  0.015 mL vs treated 0.184  0.039 mL [P < .01]) and 21
days (control weight 0.306  0.053 g vs treated 0.198  0.043 g [P < .01]: control volume 0.285  0.047 mL vs treated
0.148  0.041 mL, [P < .01]). Angiogenesis was delayed in the enoxaparin sodium-treated constructs with the absolute
vascular volume significantly decreased at 10 days (control vascular volume 0.029  0.03 mL vs treated 0.012  0.002
mL [P < .05]).
Conclusion: In this in vivo tissue engineering model, endogenous, extra-vascularly deposited fibrin volume determines
construct size and vascular growth in the first 3 weeks and is, therefore, critical to full construct development. ( J Vasc Surg
2008;48:974-85.)
Clinical Relevance: Tissue engineering is an expanding field and ultimately has the potential of growing new organs
and tissues for replacement of damaged or lost organs. The Bernard O’Brien Institute of Microsurgery (Melbourne,
Australia) has developed an in vivo model in which a surgically created arteriovenous loop (AVL) created on the rat
femoral vessels and placed in an empty poly-carbonate chamber under the groin skin exudes a fibrin matrix that fills the
chamber in the first day. Capillaries begin sprouting from the femoral vein portion of the AVL 3-5 days later, supported by the
fibrin matrix (Lokmic et al).5 The chamber is filled to about three-quarters full with vascularized connective tissue in about 3
weeks. The endogenous fibrin scaffold is an integral part of the construct. Many tissue engineering models use biological or
synthetic scaffolds to support and maintain the construct. This study looks at the significance of this endogenous fibrin scaffold
by partially inhibiting its formation using enoxaparin sodium (an inhibitor of fibrin polymerization) and subsequently
comparing with untreated controls, construct weight, and volume and vascularization over the following 3 weeks. Utilizing
endogenous fibrin scaffolds has enormous potential for in vivo tissue engineering, particularly in growing large three
dimensional vascularized tissues. Endogenous fibrin scaffolds are biologically compatible with the host and will not provoke
an inflammatory or foreign body response. This study explores the significance of this natural scaffold in determining construct
size and vascularization in an in vivo model of tissue engineering.Tissue engineering and regenerative medicine are emer-
gent fields of medicine that will have broad applications in the
management of disease and trauma. The technologies associ-
ated with these fields are multiple and include molecular and
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tation into the body. Cytoprotective therapies will comple-
ment this process, but the key to survival of implanted cells
and tissues is rapid vascularization. We have developed a
chamber for this purpose that is implanted subdermally to-
getherwith an arteriovenous fistula inset within the chamber’s
hollow interior. This configuration leads to a rapid angiogenic
burst from the fistulous loop that progressively fills the cham-
ber space. The proliferating and expanding vascularized con-
nective tissue is an ideal “bed” for the vascularization of
seeded cells and small tissue pieces. Using this approach we
have been able to grow heart tissue from neonatal cardiomy-
ocytes1 and adipose tissue from implanted muscle pieces.2
There is a need for improving the implantation efficacy of
many current cell seeding therapies. Vascularization is the
common denominator of their success.
The key intermediary to facilitate the delivery of labo-
ratory products for tissue engineering procedures will be
the vascular surgeon. He/she will critically create the vas-
cular environment that nourishes the product and ensures
maximum cell survival, whether this be an arteriovenous
fistula, pedicle, or some other novel vascular bed. The
vascular surgeon should be at the forefront of this technol-
ogy, as advisor to the bioengineer and cell biologist, as the
professional who will biopsy tissues/cells for laboratory
manipulation, and as the surgeon to create the vascular bed
and implant the chamber and the manipulated cells or
tissue.
This study addresses an aspect of the angiogenic prolif-
Fig 1. a,Diagram of the arteriovenous loop (recipient f
base in the rat groin. b,Diagram illustrating the dimensio
groin. c, Diagram of the chamber lid. (Illustrations by Deration from the arteriovenous loop (AVL) in our chamberand highlights the efficacy of fibrin as a positive influence on
tissue growth in the AVL chamber environment.
To establish new tissue growth in vivo for tissue engi-
neering purposes, a tissue engineering ‘construct’ is cre-
ated. The construct will include a scaffold that mimics the
extra cellular matrix of the tissue or organ being grown, and
usually a specific implanted cell population and/or a vascu-
lar supply. The scaffold, which may be either synthetically
or biologically derived, has a number of purposes including
the maintenance of construct size and support of implanted
cells and angiogenic growth.3 Numerous scaffolds have
been developed for tissue engineering purposes with a
variable degree of success, however, many of these scaffolds
generate foreign body responses in the developing tissue.4
In the AVL chamber model of tissue engineering, a
vein graft is microsurgically inserted between the cut ends
of the femoral artery and vein (Fig 1). The AVL is inserted
in a polycarbonate chamber without the addition of growth
factors or an exogenous scaffold. The microsurgical proce-
dure leads to the deposition within the first day (Dr A
Messina, personnel communication) of a fibrinogen-based
exudate largely exuded from the anastomosis, that is pro-
tected in vivo by the walls of the polycarbonate chamber.5
Observations of the AVL without the chamber at the same
site indicate dissipation of the fibrin exudate if the AVL is
not contained within a chamber, and complete inhibition
of new tissue growth around the AVL if it is not contained
in a chamber (Kelly, JL, Messina A, manuscript in prepara-
al artery, vein and vein graft) positioned on the chamber
the components of the AVL on the chamber base in the
ina Lokmic).emor
ns oftion).
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lar wall derived mesenchymal and endothelial precursors
migrate into this fibrin scaffold largely from the recipient
vein and by 7 days a cuff of new capillaries supported by
connective tissue deposition sprout off the AVL,5 (Fig 2).
Angiogenic sprouting from the AVL is absolutely essential to
the creation of an “engineered” microcirculation in the AVL
construct. (In terms of the AVL chamber model the term
‘construct’ refers to the chamber contents, that is, the AVL
and surrounding fibrin scaffold and new tissue [blood
vessels and connective tissue] which may have grown into
the scaffold. The term construct does not include the
chamber itself).
The new tissue that grows into the fibrin scaffold is
derived from migrating cells that move from the blood
stream through the wall of the AVL and into the fibrin. The
chamber walls largely prohibit interaction with the outside
tissue. This has distinct advantages for the AVL construct,
as the chamber walls protect the fibrin scaffold in the first
Fig 2. a, Diagram of the AVL on the chamber base at
almost fills the chamber and sprouting from the recipien
early migration of cells into the fibrin scaffold, and sprout
(Illustrations by Dr Zerina Lokmic).few days and keep it intact.The result is a highly vascularized construct composed
of a complex microcirculatory network including arterioles
and venules connected by the AVL to the systemic circula-
tion. Capillary sprouting off the AVL is an advantage as this
directly connects the new microcirculation to the systemic
circulation and means that as the new microcirculation
arises from a clearly defined vascular pedicle it can be readily
surgically transplanted to other sites.
Interestingly, angiogenesis (development of the new
vessels from pre-existing vessels) appeared to cease once the
edge of the fibrin scaffold was reached by the sprouting
capillaries5 suggesting that the volume of fibrin scaffold
may exert limitations on construct growth.
The role of fibrin in angiogenesis is best observed
during wound healing. Here the endogenously deposited
fibrin is a polymerized scaffold containing growth factors
and cytokines which enable migration of inflammatory
cells, myofibroblasts, and angiogenic capillaries.6,7 Angio-
genic growth factors - vascular endothelial growth factor
oximately 7-10 days, illustrating the fibrin scaffold that
oral artery and vein. b, Diagram illustrating in detail the
capillaries from the recipient vein into the fibrin scaffold.appr
t fem
ing of(VEGF)6 and fibroblast growth factor-2 (FGF-2)7 can bind
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capillaries in the tissue adjacent to the deposited fibrin
commence development with the proteolysis of the pre-
existing basement membrane8 and proliferation of migrat-
ing endothelial cells under the influence of VEGF, FGF-2,
and transforming growth factor- (TFG- ).8,9 The prolif-
erating capillary sprouts migrate into the fibrin eventually
becoming functional blood vessels. This same early cell-
supportive role of endogenously deposited fibrin scaffold was
observed in the formation of surgically created rat AVL tissue
engineering constructs.5
The hypothesis of this study is that chronic administra-
tion of enoxaparin sodium will inhibit fibrin and vascular-
ized tissue formation inside experimental subcutaneous
polycarbonate chambers containing a surgically-created
AVL.
The aim of this study was to examine the significance of
endogenously deposited fibrin scaffold in the tissue and
microvascular development of the AVL construct by inhib-
iting the fibrin polymerization, and, therefore, deposition
using the low molecular weight heparin, enoxaparin so-
dium. Separate groups of animals (n 6/timepoint) in the
control (saline-treated) and experimental series were exam-
ined at 3, 10, and 21 days for construct weight and volume,
morphology and morphometric analysis of tissue compo-
nents: fibrin, connective tissue, and blood vessels. The
selection of these time points was based on a previous study
where, in the absence of exogenously added scaffolds or
growth factors, the peak of construct weight and volume
was observed at 7 days while the peak percent vascular
volume was observed at 10 days.5
METHODS AND MATERIALS
Animals. Six male Sprague-Dawley rats (ARC, Perth,
Western Australia) weighing 280-320 grams were used for
each time point (3, 10, and 21 days) in the control and
experimental series. All experimental procedures were ap-
proved by the Animal Ethics Committee of St Vincent’s
Hospital, Melbourne, Australia, and were conducted in
accordance with the Australian National Health and Med-
ical Research Council guidelines for the care and mainte-
nance of animals.
Pre-operative treatment. Enoxaparin sodium binds
to anti-thrombin III leading to inhibition of thrombin
generation, and inhibition of Factor Xa, as well as induction
of a sustained release of tissue factor pathway inhibitor.10
The end point of enoxaparin sodium treatment is the
inhibition of fibrin polymerization within the circulatory
system. For this reason, enoxaparin sodium is used in
pre-operative and post-operative care of patients undergo-
ing surgery to prevent post-operative thrombotic compli-
cations. The pre-operative doses used in human patients in
clinical settings are 0.3 mg/kg weight (for patients with
low risk of developing thrombosis), 0.6 mg/kg (for pa-
tients with high risk of developing thrombosis), and a
post-operative dose 1.5 mg/kg.11-13
Therapeutic doses of enoxaparin sodium reported in
the literature for animal experimentation vary widely.14-17An increased occurrence of hemorrhage has been reported
when doses greater than 4mg/kg are used.10 Other studies
indicate that in rats, enoxaparin sodium can be adminis-
tered at the same doses as in human subjects.18-20 In this
study, the experimental rats (Series II) were injected intra-
peritoneally with 0.6 mg/kg enoxaparin sodium (Aventis
Pharma Pty Ltd, Paris, France) 2 hours prior to surgery
while control rats (Series I) received an equivalent volume
of drug vehicle, normal saline. No adverse signs of hemor-
rhage were subsequently seen in any enoxaparin sodium-
treated rats.
Our previous studies indicate that the fibrin accumula-
tion is an immediate process commencing as the AVL
conducts a blood flow, (day 1) and continues to a lesser
extent (days 5-21) through the action of “leaky” new
capillaries. The pre-operative and 6-hour post-operative
dose will prevent the immediate deposition (day 1). The
daily post-operative administration aims to reduce further
deposition from “leaky” capillaries that are just forming
(days 5-21).
Creation of the AVL chamber model. The rats were
anesthetized by intraperitoneal injection of phenobarbi-
tone (30 mg/kg), and an AVL surgically created by inter-
posing an 11 mm vein graft harvested from the left femoral
vein, between the proximal stumps of the divided right
femoral artery and vein as previously described5 (Fig 1, a,
b). A sterile non-porous polycarbonate chamber base was
placed under the AVL (approximately 3-4 mm of recipient
artery and vein were inside the chamber) and the base
sutured in position with 6.0 nylon sutures. The AVL was
positioned in the chamber using the cut superficial inferior
epigastric vein branches (vessel tags) as the anchoring
points of the loop to the chamber (Fig 1, b), by sandwich-
ing the tags between the non-porous polycarbonate cham-
ber base and lid when the chamber was closed. The apposed
edges of the wound were sutured with 6.0 nylon sutures.
Post-operative treatment. Six hours post-surgery,
the rats were injected with saline (Series I) or 0.6 mg/kg
weight dose of enoxaparin sodium (Series II) and moni-
tored for post-operative complications (ie, hemorrhage).
Thereafter, the rats were injected daily with saline (Series I)
or 1.5 mg/kg of enoxaparin sodium (Series II) for the
duration of the study.
Anti-factor Xa activity. The in vivo activity of enox-
aparin sodium was assessed 1.5 hours after the last enox-
aparin sodium administration, in 10 randomly selected
treated rats (all time points included) (Series II, n 6) and
control rats (Series I, n 4). Anesthetized rats had 2 mL of
whole blood aspirated via cardiac puncture into a blood
tube containing 3.2% buffered trisodium citrate anticoag-
ulant (BD Vacutainer, Franklin Lakes, NJ). The samples
were analyzed for anti-factor Xa activity21 on a STAGO
STAR coagulation analyzer.
AVL chamber retrieval, weight, and volume dis-
placement measurements. Two hours prior to chamber
retrieval, the rats were injected with saline (Series I) or 1.5
mg/kg enoxaparin sodium (Group II) and then anesthe-
tized with phenobarbitone (30 mg/kg). The constructs
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mentmeasurements were performed as described previously.5
The AVL construct was fixed by immersion in 4% parafor-
maldehyde, cut into 1-mm thick vertical slices, and pro-
cessed into paraffin for routine histology. Animals were
euthanized by intraperitoneal injection of Lethobarb (200
mg/kg, Virbac, Peakhurst, Australia).
Histology. To aid the morphometric counting to de-
termine the absolute volume of fibrin, connective tissue,
and blood vessels in the constructs, 3 m-thick consecutive
paraffin sections were dewaxed, hydrated, and stained with
hematoxylin and eosin (H&E), Masson’s Trichrome stain to
identify collagen, Fraser-Lendrum stain to localize fibrin22
and immunohistochemically with Bandeiraea Simplicifolia
lectin (Vector Laboratories, Burlingame, Calif) to identify
blood vessels.23 The tissue was examined under a light micro-
scope and photographed with a Zeiss digital camera (Carl
Zeiss, Jena, Germany).
Morphometric analysis. To determine the volume of
tissue components (AVL, fibrin matrix, connective tissue,
and new blood vessels), lectin labeled sections were exam-
ined under x20 magnification with a 100 point test grid
eyepiece lens placed over the sections. A random micro-
scopic field was selected as a starting point and points falling
over the AVL, fibrin matrix, connective tissue, and new
blood vessels counted in every fifth field by an observer
(Z.L.) blinded to the identity of the tissue. These propor-
tional counts of tissue components were expressed as a
percentage of the total points counted (total points repre-
senting the whole construct).24 This measurement is
termed the percent volume of a tissue component. To
determine the absolute volume of a tissue component, the
percent volume of the tissue component was multiplied by
the volume displacement of that construct (taken at har-
vest) to obtain the volume of that particular tissue compo-
nent.24
Statistical analysis. The weight, tissue volume, and
anti-factor Xa data are expressed as mean  SD. Morpho-
metric results are expressed as mean  SEM of grouped
data where n  number of rats per group. For statistical
comparison between Series I and II, the means were ana-
lyzed using univariate analysis of variance (GraphPad Prism
Software, version 4.0; La Jolla, Calif). The results were
considered statistically significant when P  .05.
For comparison of patency rates between enoxaparin
sodium-treated and control Fisher’s exact test was used.
RESULTS
Assessment of anti-factor Xa activity. Blood analysis
for anti-factor Xa activity showed that the mean value for
saline-treated (Series I) rats was 0.26 0.02 IU/mL while
for the treated rats (Series II) it was 1.28  0.32 IU/mL.
These results indicated that the therapeutic dose of enox-
aparin sodium at 1.5 mg/kg was sufficient to inhibit intra-
vascular fibrinogen polymerization.
Animal exclusions and AVL patency rate. Seven rats
were excluded from the study, 3 in the control series (1 at
10-days, and 2 at 21-days) and 4 in the treated series (1 at3 days, 1 at 10 days, and 2 at 21 days) due to infection, AVL
occlusion (control groups only), and hematoma formation.
Three days is too early to assess patency in this model.
At 10 days, the patency was identical in both groups at
100%. At 21 days, the enoxaparin sodium-treated group
maintained 100% patency, whilst the control group had 4
of 6 AVLs patent (67% patency rate). There was no signif-
icant difference between the patency rates of the control
and enoxaparin sodium -treated groups (P  .47, Fisher’s
Exact test).
Macroscopic appearance. The 3-day control con-
structs, consisted largely of a fragile gel-like yellow fibrin
scaffold surrounding the AVL (Fig 3, a). These specimens
contained small patches of hemorrhage randomly distrib-
uted throughout the fibrin scaffold. In contrast, in the
3-day enoxaparin sodium-treated rats, the AVL constructs
appeared smaller and the fibrin scaffold was firm, white,
rubbery, and heavily hemorrhagic around the vein graft
(Fig 3, b).
Ten-day control constructs were characterized by new
tissue deposited around the AVL. The fibrin scaffold was
predominantly of yellow color with areas of hemorrhage
associated with the developing vascularized tissue. Similar
observations were made in 10-day enoxaparin sodium-
treated constructs, except that these constructs were more
hemorrhagic and the fibrin scaffold was white and rubbery.
By 21 days, the majority of control constructs contained
residual fibrin scaffold at the periphery of the construct (Fig
3, c), whereas the enoxaparin sodium-treated constructs
were smaller and appeared quite hemorrhagic with little
fibrin visible at the periphery of the construct (Fig 3, d).
Tissue weight and volume. The inhibition of fibrin
polymerization by enoxaparin sodium resulted in the de-
velopment of smaller constructs by weight and volume
compared to control at all time points (Fig 4, a, b). At 10
days, enoxaparin sodium-treated constructs were signifi-
cantly smaller by weight (0.228 0.048 g compared to the
control group: 0.337  0.016 g, P  .001) and volume
(0.184 0.039mL compared to the control group: 0.317
0.015 mL, P  .01). These differences persisted at 21 days
with weight (0.198  0.043 g compared to the control
group: 0.306 0.053 g, P .01) and volume of constructs
(0.148 0.041mL compared to the control group: 0.285
0.047 mL, P .01) (Fig 4, a, b).
Morphology. At 3 days, the control AVL constructs
were characterized by formation of a fibrin exudate around
the AVL (Fig 5, a). The fibrin scaffold consisted of long
uniform fibers and was deposited in layers in alternate
arrangements of thin wispy strands of fibrin and slightly
more dense areas of fibrin, suggesting gradual deposition.
The fibrin matrix was infiltrated with inflammatory cells
and early vessel sprouts in three constructs. Spindle-shaped
cells were observed in close vicinity to the vein wall (Fig 5,
c), but were also scattered throughout the fibrin scaffold.
These cells were observed either alone or in contact with
another “like” cell.
In 3-day enoxaparin sodium-treated animals, the spindle-
shaped mesenchymal cells were observed only in the areas
surface. P, pedicle (femoral artery and vein at chamber entran
volume (P  .01).
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constructs, fibrin strands appeared as fragmented and short
(Fig 5, d). The major histological difference between con-
trol and enoxaparin sodium-treated constructs was the
presence of significant hemorrhage and inflammation in the
fibrin scaffold of treated constructs (Fig 5, b, d). None of
the enoxaparin sodium-treated constructs showed signs of
thrombus formation in the AVL or demonstrated capillary
sprouting.
In 10-day control constructs different stages (zones) of
construct development were evident (Fig 6, a, c). The
innermost zone was the maturing vascularized connective
tissue that formed a cuff around the AVL adjacent to the
AVL adventitial surface. External to this mature zone was a
prominent, wide capillary proliferative zone completely
surrounding the tissue cuff. External to the proliferative
zone was a thin layer of hemorrhage associated with hyper-
permeable vessels which was part of the most peripheral
zone of the construct, the fibrin scaffold. New blood vessels
within the mature zone and proliferative zone were clearly
perfused with blood in all specimens. The proliferative zone
was ‘invading’ the extensive fibrin scaffold associated with
the periphery of the specimen adjacent to the chamber. The
first arterioles were observed close to the AVL in all control
constructs.
In 10-day enoxaparin sodium-treated constructs (Fig
m–treated constructs at harvest. a, Three-day control
f translucent yellow fibrin (F). b, Three- day enoxaparin
an the control (a) and the fibrin matrix includes a large
ruct. Note that the outer surface of the construct still
n sodium-treated construct. Note that the outer surface
tissue (arrow). Haemorrhage also covers the construct
ce); C, chamber base.Fig 3. Macroscopic view of control and enoxaparin sodiu
constructs. Note that the major part of the construct consists o
sodium-treated construct. Note that the construct is smaller th
amount of blood (arrow). c, Twenty-one-day control const
demonstrates a fibrin layer (F). d, Twenty-one-day enoxapari
does not demonstrate fibrin, but rather more solid connectiveFig 4. a, Weight and b, volume of control and enoxaparin sodi-
um-treated constructs at 3, 10, and 21 days. At 10 days (*)
enoxaparin sodium-treated constructs were significantly smaller by
weight (P  .001) and volume (P  .01). These significant
reductions persisted at 21 days (**) for both weight (P .01) and6, c, d, e), most of the fibrin was replaced by vascularized
). Sc
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present close to the external boundary of the construct,
surrounded by a narrow area of hemorrhagic fibrin scaffold
(Fig 6, d, e). Only two of six treated constructs demon-
strated arteriolar development at 10 days.
In 21 day control constructs the fibrin scaffold was
present at the periphery of the construct surrounding a
prominent capillary proliferative zone, characterized by
immature hyperpermeable vessels (Fig 7, a, c). The fibrin
scaffold continued to act as a provisional matrix for cellular
migration from the proliferative zone.
In 21-day enoxaparin sodium-treated constructs, the
fibrin scaffold was almost non-existent. There was no cap-
illary proliferative zone and the majority of specimens ap-
peared to have reached their full development prior to 21
days (Fig 7, c, d, e).
Morphometry: absolute volume of fibrin, connec-
tive tissue, and new blood vessels. Absolute fibrin vol-
ume decreased gradually over time in control and enoxapa-
rin sodium-treated constructs (Fig 8, a). Absolute fibrin
volume was always less, but not significantly so in the
Fig 5. Three-day control and enoxaparin sodium–treat
The AVL is surrounded by an extensive fibrin exudate (p
[area within box in (a)] demonstrating the arteriovenous
(F) showing as purple fibers, infiltrated by inflammatory
close to the AVL wall (dotted arrow). c, Three-day enoxa
of fibrin (F, pinkish material) and larger areas of haem
three-day enoxaparin sodium-treated construct [area w
region of vein graft) surrounded by areas of fragmented fi
yellow). Occasional inflammatory cells are present (arrowenoxaparin sodium-treated groups at each time point. The10-day time point difference neared significance (P 
.058).
The absolute volume of new connective tissue in-
creased from 3 to 10 days in both control and enoxaparin
sodium-treated constructs (Fig 8, b) and stabilized thereaf-
ter. The enoxaparin sodium-treated constructs demon-
strated a reduced connective tissue volume compared to
control at all time points, although the differences were not
significant (Fig 8, b).
In 3-day control constructs, angiogenesis had com-
menced and vascular volume was small (0.0004mL), whilst
in enoxaparin sodium-treated constructs angiogenesis was
not evident. Throughout the study period, absolute vascu-
lar volume was decreased in enoxaparin sodium-treated
constructs (Fig 8, c) compared to controls, and was signif-
icantly different at 10 days (0.012  0.002 mL for treated
vs 0.029  0.03 mL for controls, P  .05).
Definite trends were observed in the diminished vol-
ume of fibrin, connective tissue, and new blood vessels in all
enoxaparin sodium treated groups compared to control,
with only the 10-day vascular volume being significantly
nstructs. (Fraser-Lendrum stain). a, Three-day control.
area). b,Higher power micrograph of three day control
W, region of femoral vein) surrounded by fibrin exudate
blue nuclei, arrow). Also evident are mesenchymal cells
sodium-treated construct showing relatively small areas
ge (H, yellow areas). d, Higher power micrograph of
box in (c)] demonstrating the arteriovenous wall (W,
F, and dotted arrow) and larger areas of haemorrhage (H,
ale bars (a and c)  500 m, (b and d)  100 m.ed co
urple
wall (
cells (
parin
orrha
ithin
brin (different. It is possible that a Type II error has occurred and
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DISCUSSION
During wound healing or hemostatic imbalances, a
complex cascade of events leads to polymerization of solu-
ble fibrinogen, a 340 kDa glycoprotein present in high
concentrations in the circulating blood, by thrombin into
the insoluble, cross-linked fibrin clot.25 In this study, we
report that a fibrin scaffold, formed through normal phys-
iological responses following surgical formation of an AVL
and protected by a chamber space, has a pivotal role in the
development of a surgically generated tissue engineered
microcirculatory network in vivo. Furthermore, the quality
and volume of deposited fibrin determines the whole con-
struct size, the total tissue volume, and rate of maturation
Fig 6. Ten-day control and enoxaparin sodium–treated
(b) enoxaparin sodium–treated constructs both demonst
connective tissue (M) and fibrin (F) external to the n
proliferative zone. Scale bars  500 m. b, and d, Hi
enoxaparin sodium–treated constructs (d) [areas in boxe
capillaries (arrows) in collagenous connective tissue. Extern
100 m. e, Higher magnification of tissue edge of treate
external fibrin (F) scaffold. Scale bar 20 m.of new blood vessels in the construct.Early deposited fibrin in this model provides a three-
dimensional scaffold that supports migration of inflamma-
tory cells, vascular precursors and myofibroblasts, and the
formation of a new vascular network.5 These events are
likely to be controlled by the presentation of cytokines and
growth factors, bound to fibrin, and available immediately
upon cleavage to the migrating cells,6,7 and, cell integrin-
fibrin matrix interaction.26,27 For example, the cellular
recognition of the Arg-Gly-Asp (RGD) peptide in fi-
bronectin is mediated by the v3 integrin, resulting in the
activation of various signaling pathways governing cellular
shape, migration, and function.28,29 Subsequently many
synthetic matrices have been modified to include the RGD
sequence on their surface28 to reflect fibrin structure and
generate a tissue construct with specific cellular composi-
tion and possibly a reduced foreign body response to the
tructs. (Fraser-Lendrum stain). a, Ten-day control and
a central AVL surrounded by maturing blood vessels in
lood vessels. The arrow indicates the position of the
power of maturing tissue from 10-day control (b) and
) and (c)] demonstrating the AVL wall (W) and mature
the mature tissue is the proliferative zone (P). Scale bars
struct showing a new capillary (arrow) growing into thecons
rating
ew b
gher
s in (a
al to
d consynthetic part of the hybrid scaffold.28,30
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enoxaparin sodium in AVL constructs has resulted in
reduced fibrin deposition in the chamber space and
changes in fibrin quality, apparent histologically as frag-
mented fibrin strands. This effect was also evident in the
form, of a white, rubbery macroscopic appearance of the
fibrin in the treated constructs vs yellow, gel-like fibrin
scaffold in the control constructs. This change in physical
properties of the fibrin scaffold and the delayed migratory
pattern of mesenchymal and endothelial precursor cells sug-
gests that the structure and integrity of the fibrin is important
in the development of vascularized connective tissue in this
model. These findings support in vitro studies showing that
the polymerization of fibrin under different pH affects the
Fig 7. Twenty one-day control and enoxaparin sodiu
one-day control and (c) enoxaparin sodium–treated co
construct tissue (M). In treated constructs (c) the new tis
and the proliferative zone is absent. In the control (a) th
was still growing. The fibrin zone was present at the perip
power of twenty one-day control (b) and enoxaparin so
demonstrating the AVL wall (W) and mature capillaries
zone (P) was seen external to the mature tissue only
magnification of tissue edge of treated construct dem
connective tissue comes to the edge of the construct
capillaries. Scale bar  20 m.in-growth of capillary tubes into the fibrinmatrix31,32 whilethe addition of low molecular weight heparin during poly-
merization reduces the in-growth of capillary tubes into
fibrin matrix.33
There are a number of studies in the literature which
suggest that low molecular weight heparins inhibit angio-
genesis34 although not all studies support this concept.35
It has also been demonstrated by Collen et al33 that low
molecular weight heparins significantly inhibit microvascu-
lar in-growth into a fibrous stroma, by altering the fibrin
matrix formed so that it is a less favorable environment for
microvascular invasion. Our study supports this later hy-
pothesis as distinct alterations in the fibrin matrix quality
were observed macroscopically and microscopically in the
treated group. Although the angiogenic process appeared
eated constructs. (Fraser-Lendrum stain). a, Twenty
cts with a central AVL surrounded by largely mature
s grown to the edge of the fibrin scaffold (dotted arrows)
liferative zone (P) persisted indicating that the construct
f the specimens. Scale bars 500 m. b, and d,Higher
–treated constructs (d) [areas in boxes in (a) and (c)]
ows) in collagenous connective tissue. The proliferative
control specimens. Scale bars  100 m. e, Higher
ating no fibrin scaffold or proliferative zone. Mature
ted arrow, compare with 4e). Solid arrows: maturingm–tr
nstru
sue ha
e pro
hery o
dium
(arr
in the
onstr
(dotsimilar in both treated and control groups of our study, the
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treated group, as too was the onset of the first microvascular
tube formation (capillary formation), and arteriole forma-
tion. In addition, the reduced fibrin volume resulting from
low molecular weight heparin treatment reduced the vol-
ume of matrix available for microvascular invasion, and
therefore reduced the time over which angiogenesis took
place and ultimately significantly reduced the weight and
volume of low molecular weight heparin (enoxaparin so-
dium) treated constructs.
In this study, the enoxaparin sodium-induced fragmen-
tation of fibrin matrix was associated with delayed cellular
migration and angiogenesis but was insufficient to com-
pletely prevent the development of vascularized connective
tissue. The delayed angiogenic development was evident by
the absence of new blood vessels in the treated constructs at
3 days, while angiogenic sprouting was present in 3 out of
6 control constructs at 3 days. At 10 days, the treated
constructs had a smaller capillary proliferative zone, a sig-
nificantly reduced vascular volume, and delayed arteriolar
development compared to controls. While these results
further support the hypothesis that the quality and volume
of the polymerized fibrin scaffold is pivotal in the develop-
ment of the new blood vessels as well as the determinant of
construct size, vascular volume, and rate of vascular matu-
ration in AVL constructs, it cannot be excluded that low
molecular weight heparin enoxaparin sodium might have a
detrimental effect on microvascular endothelial cell prolif-
eration34 subsequently leading to a reduced vascular vol-
Fig 8. Morphometry. a, Absolute volume of fibrin in co
ing reduced fibrin volumes in treated constructs through
controls and enoxaparin sodium–treated constructs, de
constructs. c, Throughout the study period absolute v
constructs. This difference was statistically significant at 1
for controls, P  .05.ume as reported here. A statistical difference in absolutevascular volume was not observed at 21 days, and is most
likely due to partial microcirculatory remodeling already
taking place in the 21-day control constructs.5
The study reported here has demonstrated that in
treated 21-day constructs when no fibrin scaffold was
present, the proliferative zone no longer existed indicating
that the vascular and tissue growth ceased prior to 21 days
in the treated group. In contrast, in 21-day controls, where
an intact fibrin matrix was still present, angiogenesis con-
tinued as evident by a presence of a persistent proliferative
zone indicating a further growth potential. Therefore, AVL
construct development is limited by the availability of the
fibrin scaffold deposited around the AVL i.e. decreased
fibrin matrix deposition around the AVL results in de-
creased volume of generated vascularized tissue.
Although the concentration of enoxaparin sodium
used in this study was sufficient to reduce intravascular
fibrinogen polymerization, a complete inhibition of extra-
vascular fibrin formation around the AVLwas not achieved.
This suggests that enoxaparin sodium might not act extra-
vascularly in the same manner as intra-vascularly either
because a significant amount of active extra-vascular profi-
brotic factors are present in the deposited scaffold (but not
in the blood), or alternatively, once extra-vascular, enox-
aparin sodium was unable to bind to anti-thrombin III and
completely inhibit thrombin generation. This would sub-
sequently lead to activation of factor X and fibrin polymer-
ization once the factor reached the extra-luminal surface of
and enoxaparin sodium–treated constructs demonstrat-
e study. b, Absolute volume of new connective tissue in
trating lower volumes throughout the study in treated
r volume was decreased in enoxaparin sodium-treated
s (*), 0.012 0.002 mL for treated vs 0.029 0.03 mLntrol
out th
mons
ascula
0 daythe AVL.
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served in the enoxaparin sodium-treated constructs indicat-
ing that use of low molecular weight heparins such as
enoxaparin sodium will decrease the AVL occlusion rate
otherwise observed in a series extending to 16 weeks at
15.1% of all untreated AVL constructs5 and in this study to
a decline in untreated AVL construct patency from 100% at
10 days to 67% at 21 days. However, the use of enoxaparin
sodium as an anticoagulant would result in generation of
smaller AVL constructs which should be taken into consid-
eration if a large three-dimensional tissue or organ is re-
quired.
We have previously noted that occlusion of the AVL
does not in fact lead to an adverse outcome, but rather
prolongs angiogenesis and increases construct size if occlu-
sion occurs after approximately one week.3 The AVL cham-
ber model has considerable plasticity and AVL occlusion
after 7 days has no adverse effect on the new microcircula-
tory bed or supporting connective tissue and is, therefore,
not a significant issue in this model.
An alternative to in vivo generation of fibrin matrix are
the commercially available fibrin sealants which are com-
posed of high concentrations of plasma derived complexes
of purified pathogen inactivated human fibrinogen and
thrombin.36 Fibrin sealants are semi-rigid, water-resistant
polymers which are relatively inert. This inertness is de-
signed to reduce inflammation, cellular migration, foreign
body reaction, and cellular necrosis associated with the use
of fibrin sealants.37,38 However, the ability to support the
development of a vascularized connective tissue construct
seems to be dependent of the concentration of the fibrin
present in the sealant mixture. For example Cassell et al
have shown that the use of commercial fibrin preparations
at 20 and 80 mg/mL resulted in the development of
smaller tissue constructs with decreased vascular volume.39
Similar observations have been reported by Polykandriotis
et al where a fibrin sealant used at 30 mg/mL resulted in
delayed angiogenesis.40 However, Arkudas et al41 have
shown that both VEGF and basic fibroblast growth factor
can be incorporated into this fibrin sealant (10 mg/mL of
fibrin, 2 IU/mL of thrombin and 1500 KIE/mL aproti-
nin) with a resulting increased vascular density at 2 weeks
compared to constructs containing the same fibrin sealant
matrix without growth factors. Better understanding of
biochemical properties of fibrin and cell-fibrin scaffold in-
teraction should enable further modifications of the chem-
ical composition of fibrin-based products that may improve
their use in tissue engineering.
CONCLUSION
The volume and integrity of fibrin matrix in AVL
constructs acts as a limiting factor in AVL construct devel-
opment since:
● Fibrinmatrix provides a provisional scaffold for cellular
migration and connective tissue deposition. Changes
in fibrin polymerization alter the pattern of cellularmigration, delay angiogenesis, and arteriole matura-
tion.
● A decrease in fibrin polymerization and the subsequent
reduced volume of deposited fibrin in the chamber
significantly reduces the volume and weight of tissue
constructs at 10 and 21 days, and significantly reduces
absolute vascular volume at 10 days.
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